-
Mashup Score: 5
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 8Adrenal myelolipomas - 7 month(s) ago
Adrenal myelolipomas are benign, lipomatous tumours with elements of myeloid cells, most of which present as adrenal incidentalomas and comprise 3·3–6·5% of all adrenal masses. Adrenal myelolipomas are usually unilateral (in 95% of cases), variable in size, most often found during midlife, and affect both sexes almost equally. On imaging, adrenal myelolipomas show pathognomonic imaging features consistent with the presence of macroscopic fat. Large adrenal myelolipomas can cause symptoms of mass effect, and can occasionally be complicated by haemorrhage.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 1Adrenal crises in older patients - 7 month(s) ago
Adrenal crises are severe manifestations of adrenal insufficiency that result in hospital admission and incur a risk of cardiovascular events, acute renal injury, and death. Evidence from population-based studies indicate that adults older than 60 years have the highest adrenal insufficiency incidence, contribute to the highest number of adrenal crises, and have the highest age-specific incidence of adrenal crisis, which doubles between the age groups of 60–69 years and 80 years or older. Older patients might be more susceptible to adrenal crises because of a higher prevalence of comorbidities and a consequently higher risk of acute illness.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 2
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 2
Recently, a man aged 50 years came to my office. He had received surgery for a right-sided non-functional adrenocortical carcinoma measuring 11 cm in diameter and had been referred to discuss adjuvant treatment. Based on adrenal histology findings, he had a European Network for the Study of Adrenal Tumors (ENS@T) tumour stage II, which means no lymph node metastases, and a [18F]fluorodeoxyglucose-PET scan had ruled out distant metastasis.1 Fortunately, he had undergone oncological tumour resection resulting in complete resection.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0Glands Notepad - 7 month(s) ago
Introducing All Glands Notepads – Embrace the power of pen and paper!
Source: www.endocrine.orgCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 2
For adrenal insufficiency (AI), reducing false positives means more than reducing resource utilization. Treatments like glucocorticoid replacement therapy can cause serious harm in people who do not actually have AI.
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1CEU 2023 | September 21-23, 2023 - 8 month(s) ago
Join us on September 21-23 for the Clinical Endocrinology Update (CEU) 2023 online meeting.
Source: ceu2023.endocrine.orgCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0CEU 2023 | September 21-23, 2023 - 8 month(s) ago
Join us on September 21-23 for the Clinical Endocrinology Update (CEU) 2023 online meeting.
Source: ceu2023.endocrine.orgCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0Beyond the Bench: Q&A with William Rainey, PhD - Endocrine News - 9 month(s) ago
Honored with the Endocrine Society’s 2023 Outstanding Mentor Laureate Award, William Rainey, PhD, talks to Endocrine News about his mentoring philosophy, how he’s expanding adrenal research throughout academia, and how his own experiences as a mentee has informed his role as a mentor. It starts with his belief that mentorship extends beyond the laboratory doors….
Source: Endocrine NewsCategories: Endocrinology, Latest HeadlinesTweet
#Adjuvant #mitotane versus surveillance in low-grade, localised #adrenocortical #carcinoma (#ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study https://t.co/Ujp2h9u9hd #adrenal #ACC #OpenAccess https://t.co/lvnr6A5ESs